BridgeBio Pharma (BBIO) EBIAT (2018 - 2026)
BridgeBio Pharma recorded quarterly EBIAT of -$166.6 million in Q1 2026, up 14.43% quarter-over-quarter from -$194.6 million in Q4 2025, and up 1.8% year-over-year from -$163.6 million in Q1 2025.
BridgeBio Pharma's EBIAT history runs 9 years deep, the most recent figure standing at -$166.6 million for Q1 2026.
- In Q1 2026, EBIAT rose 1.8% year-over-year to -$166.6 million; the TTM figure through Mar 2026 stood at -$729.9 million (down 7.84% YoY), while the FY2025 annual figure was -$732.9 million, down 34.89% from the prior year.
- EBIAT came in at -$166.6 million for Q1 2026 at BridgeBio Pharma, up from -$194.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$2.6 million in Q2 2022 to a low of -$267.4 million in Q4 2024.
- A 5-year average of -$151.8 million and a median of -$166.6 million in 2026 frame the typical range for EBIAT.
- Across the five-year window, EBIAT soared 97.49% in 2022 and slumped 6179.91% in 2023, its largest moves.
- BridgeBio Pharma's EBIAT stood at -$140.6 million in 2022, then declined by 21.17% to -$170.3 million in 2023, then sank by 56.98% to -$267.4 million in 2024, then gained by 27.21% to -$194.6 million in 2025, then gained by 14.43% to -$166.6 million in 2026.
- According to Business Quant data, EBIAT over the past three periods registered -$166.6 million, -$194.6 million, and -$184.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -166.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -166.56 Mn |
| Dec 31, 2025 | -194.64 Mn |
| Sep 30, 2025 | -184.94 Mn |
| Jun 30, 2025 | -183.76 Mn |
| Mar 31, 2025 | -169.61 Mn |
| Dec 31, 2024 | -267.39 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -36.16 Mn |
| Dec 31, 2023 | -170.33 Mn |
| Sep 30, 2023 | -179.49 Mn |
| Jun 30, 2023 | -160.70 Mn |
| Mar 31, 2023 | -142.73 Mn |
| Dec 31, 2022 | -140.57 Mn |
| Sep 30, 2022 | -140.19 Mn |
| Jun 30, 2022 | -2.56 Mn |
| Mar 31, 2022 | -201.33 Mn |
| Dec 31, 2021 | -152.28 Mn |
| Sep 30, 2021 | -161.02 Mn |
| Jun 30, 2021 | -102.07 Mn |
| Mar 31, 2021 | -171.08 Mn |
| Dec 31, 2020 | -135.03 Mn |
| Sep 30, 2020 | -130.17 Mn |
| Jun 30, 2020 | -136.21 Mn |
| Mar 31, 2020 | -104.08 Mn |
| Dec 31, 2019 | -84.15 Mn |
| Sep 30, 2019 | -60.66 Mn |
| Jun 30, 2019 | -69,000.00 |
| Mar 31, 2019 | -69.44 Mn |
| Dec 31, 2018 | -49.24 Mn |
| Sep 30, 2018 | -42.08 Mn |
| Jun 30, 2018 | -26.55 Mn |